Skip to main content
Erschienen in: Annals of Surgical Oncology 11/2007

01.11.2007 | Thoracic Oncology

Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin

Erschienen in: Annals of Surgical Oncology | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

Background

Dramatic responses to chemotherapy are occurring more and more frequently in patients with multiple colorectal liver metastases (LMs), leading to resection. In a few patients, some LMs vanish on imaging studies, remain undetected during hepatectomy, and are left in place, which defines the “missing LMs.” The aim of our study was to assess the long-term outcome of such “missing LMs.”

Patients

Between January 1999 and June 2004, among 228 patients treated for colorectal LMs, missing LMs were observed in 16 patients. All the patients were operated within 4 weeks of imaging. Hepatic arterial infusion (HAI) with oxaliplatin was administrated in 12 patients (75%): seven before hepatectomy and five after.

Results

Overall, 69 missing LMs were diagnosed and left in place. Among the persistent LMs resected, a complete pathological response was significantly more often observed in the group with preoperative HAI (6 of 7), than in the group without (2 of 9, P < .02). With a mean follow-up of 51 months (24–90), missing LMs did not reappear in 10 patients (62%). Adjuvant HAI was significantly correlated with the definitive eradication of missing LMs (P < .01), as it was not a complete pathological response. The overall 3-year survival rate of these highly selected 16 patients was 94%.

Conclusion

Colorectal LMs under chemotherapy that vanish on high-quality imaging studies, remain undetected during hepatectomy, and are left in place, are definitively cured in 62% of cases. This excellent result seems to be due to the administration of adjuvant hepatic arterial infusion of chemotherapy and should stimulate new investigations.
Literatur
1.
Zurück zum Zitat Ducreux M, Ychou M, Laplanche A, Gamelin, Lasser P, Husseini F, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the FNLCC. J Clin Oncol 2005;23:4881–7 Ducreux M, Ychou M, Laplanche A, Gamelin, Lasser P, Husseini F, et al. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the FNLCC. J Clin Oncol 2005;23:4881–7
2.
Zurück zum Zitat Elias D, Lasser P, de Baere B, Doidy L, Billard V, Spencer A, et al. Intermittent exclusion of the liver without vena cava clamping during major hepatectomy. Br J Surg 1995;82:1535–9PubMedCrossRef Elias D, Lasser P, de Baere B, Doidy L, Billard V, Spencer A, et al. Intermittent exclusion of the liver without vena cava clamping during major hepatectomy. Br J Surg 1995;82:1535–9PubMedCrossRef
3.
Zurück zum Zitat Elias D, Roche A, Vavasseur D, Lasser Ph. Induction d’une hypertrophie d’un petit lobe gauche hépatique avant hépatectomie droite élargie, par embolisation portale droite pré-opératoire. Ann Chir 1992;46:404–10PubMed Elias D, Roche A, Vavasseur D, Lasser Ph. Induction d’une hypertrophie d’un petit lobe gauche hépatique avant hépatectomie droite élargie, par embolisation portale droite pré-opératoire. Ann Chir 1992;46:404–10PubMed
4.
Zurück zum Zitat Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052–61PubMedCrossRef Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, et al. Tumor progression while on chemotherapy: A contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004;240:1052–61PubMedCrossRef
5.
Zurück zum Zitat Allen PJ, Kemeny N, Jarnagin W, de Matteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109–15PubMedCrossRef Allen PJ, Kemeny N, Jarnagin W, de Matteo R, Blumgart L, Fong Y. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003;7:109–15PubMedCrossRef
6.
Zurück zum Zitat Adam R, Avisar A, Giachetti S, Azoulay D, Castaing D, Kustlinger F, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal liver metastases. Ann Surg Oncol 2001;8:347–53PubMedCrossRef Adam R, Avisar A, Giachetti S, Azoulay D, Castaing D, Kustlinger F, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal liver metastases. Ann Surg Oncol 2001;8:347–53PubMedCrossRef
7.
Zurück zum Zitat O’Connell MJ, Nagorney DM, Bernath AM, Schoeder G, Fitzgibbons RJ, Mailliard JA, et al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998;16:2528–33PubMed O’Connell MJ, Nagorney DM, Bernath AM, Schoeder G, Fitzgibbons RJ, Mailliard JA, et al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998;16:2528–33PubMed
8.
Zurück zum Zitat Porta C, Danova M, Accurso S, Tinelli C, Girino M, Ricardi A, et al. Sequential intrahepatic and systemic fluoroperimidine-based chemotherapy for metastatic colorectal cancer confined to the liver: a phase II study. Cancer Chemother Pharmacol 2001; 47:423–8PubMedCrossRef Porta C, Danova M, Accurso S, Tinelli C, Girino M, Ricardi A, et al. Sequential intrahepatic and systemic fluoroperimidine-based chemotherapy for metastatic colorectal cancer confined to the liver: a phase II study. Cancer Chemother Pharmacol 2001; 47:423–8PubMedCrossRef
9.
Zurück zum Zitat Maire F, Malka D, Elias D, Boige V, Lièvre A, Louafi S, et al. Hepatic arterial infusion oxaliplatin and intravenous LV5FU2 after resection of colorectal liver metastases. Eur J Cancer 2005; 3, Vol 2: p 190; A670 Maire F, Malka D, Elias D, Boige V, Lièvre A, Louafi S, et al. Hepatic arterial infusion oxaliplatin and intravenous LV5FU2 after resection of colorectal liver metastases. Eur J Cancer 2005; 3, Vol 2: p 190; A670
10.
Zurück zum Zitat Elias D, Youssef O, Dideris L, Dromain C, Baton O, Boige V, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004;86(1):4–9PubMedCrossRef Elias D, Youssef O, Dideris L, Dromain C, Baton O, Boige V, et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004;86(1):4–9PubMedCrossRef
11.
Zurück zum Zitat Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, et al. Complete radiological response of colorectal liver metastasis (LM) after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939–44PubMedCrossRef Benoist S, Brouquet A, Penna C, Julié C, El Hajjam M, Chagnon S, et al. Complete radiological response of colorectal liver metastasis (LM) after chemotherapy: does it mean cure? J Clin Oncol 2006;24:3939–44PubMedCrossRef
12.
Zurück zum Zitat Hobday TJ, Cha SS, Sargent DJ, Buroker TR, O’Connell MJ, Goldberg RM, et al. Long term survivors of metastatic colorectal cancer treated with chemotherapy only: a NCCTG review. Proc of ASCO 2002; 693:174a Hobday TJ, Cha SS, Sargent DJ, Buroker TR, O’Connell MJ, Goldberg RM, et al. Long term survivors of metastatic colorectal cancer treated with chemotherapy only: a NCCTG review. Proc of ASCO 2002; 693:174a
Metadaten
Titel
Outcome of Posthepatectomy-Missing Colorectal Liver Metastases after Complete Response to Chemotherapy: Impact of Adjuvant Intra-arterial Hepatic Oxaliplatin
Publikationsdatum
01.11.2007
Erschienen in
Annals of Surgical Oncology / Ausgabe 11/2007
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-007-9482-9

Weitere Artikel der Ausgabe 11/2007

Annals of Surgical Oncology 11/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.